News | February 10, 2026
GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
HCG clinicians contributing to one of the largest bodies of oncology research from India
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
Subscribe To Our Newsletter & Stay Updated
